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C

hildren with chronic debilitating illness and pain are
increasingly using cannabis for medical purposes, par
ticularly when conventional treatment options have lim
ited benefit or substantial adverse effects. Caregivers are becom
ing aware of evidence that suggests medical cannabis provides
benefit for children with conditions that include drug-resistant
epilepsy, cancer pain and autism.1,2 At present, children and
youth aged 18 years and younger (henceforth referred to as chil
dren) access medical cannabis through a framework regulated
by Health Canada. In 2018, the Cannabis Act (Bill C-45) created
separate medical and recreational streams for purchasing canna
bis.3,4 Under the law, cannabis treatment for children must be
authorized by a physician or nurse practitioner, which provides
an opportunity for patient counselling. Strict production and
labelling requirements that limit contaminants and create some
consistency in cannabinoid concentrations have been instituted,
which is good for pediatric cannabis users.5 However, require
ments for physician authorization are outdated and do not
reflect the needs of pediatric patients, and product labelling
remains inadequate, as does surveillance for adverse drug reac
tions in children. Improvements in regulation are needed.
Under current regulations, health care providers must specify
the quantity of cannabis authorized for patients in grams of dried
cannabis per day. In the latter half of 2018, cannabis extracts —
preparations that have been extracted from the leaves and flow
ers (inflorescence) of Cannabis sativa — accounted for 67% of
cannabis authorized for medical purposes in Canada.6 Although
no pediatric-specific data exist, clinical experience indicates that
extracts, not dried product, are predominantly used for children.
If patients use extracts, providers must calculate a dosage con
version to complete the authorization form. The cannabinoid
content of the dried cannabis used to produce extracts varies,
which complicates the daily dosage conversion from milligrams
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increasingly using cannabis for medical purposes, particularly
when conventional treatment options have limited benefit or
substantial adverse effects.
Better processes and regulation are needed in Canada to ensure
adequate research into the effectiveness and adverse effects of
cannabis products for medical conditions in children and
adolescents.
Refinement of authorization and prescribing processes and
mandated adverse effect reporting are needed to enhance
patient safety.
Innovative mechanisms for adequate research funding that is
independent of industry influence are required to support
research that can strengthen the evidence base on the
indications, dosage, efficacy and potential toxicity of medical
cannabis for pediatric patients.

of the desired cannabinoid to grams of dried cannabis. Further
more, different processes for extracting cannabinoids from dried
cannabis plant material have the potential to give the resultant
extract a distinctive cannabinoid, terpenoid and residual solvent
profile.7 Individual licensed cannabis producers may have inter
batch variability within the same product. Dose calculation is fur
ther complicated if the patient uses more than 1 formulation.
Although licensed producers must use validated methods to
measure the concentrations of cannabinoids, Health Canada
requires only that they label the total concentrations of canna
bidiol (CBD) and tetrahydrocannabinol (THC), combining carbox
ylated and decarboxylated (activated) forms.5 This variability in
CBD and THC content, along with other undisclosed canna
binoids and terpenes, threatens safety and efficacy, deters
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Physician authorization forms for medical cannabis should
allow daily dose to be expressed as milligrams per day of the
desired cannabinoid, together with the desired ratio of canna
binoids expressed in milligrams per milliliter (e.g., 1:20
THC:CBD). To ensure patients have an uninterrupted supply of
their medical cannabis, a range of concentrations within the
ratio could be provided (e.g., 0.5–1:18–22 THC:CBD). Further
more, authorization forms should be revised to allow for more
than 1 product for the same patient.
Licensed cannabis producers should be required to clearly
display the concentrations (in mg/mL) of THC, followed by the
other most prominent cannabinoid, on product labels. Labels
should also include (in smaller font) the concentrations of the
carboxylated and decarboxylated forms of primary and other
cannabinoids with a concentration greater than 1 mg/mL. Such
consistency in labelling will help address the concerns of caregiv
ers and physicians regarding the potential psychoactive and
long-term developmental effects of THC in children.
Although it is unrealistic to require licensed producers to use
a single, standardized extraction method, they could be required
to make the extraction technique used for a given product clear,
as well as the source of the cannabis plant material. Several of
the major licensed producers have already taken the step of pre
paring products to GMP standards, and this should be required of
all medical cannabis products sold in Canada. Although transi
tioning from GPP to GMP certification may be financially chal
lenging for providers, which could lead to increased prices of
medical cannabis products, it will improve research opportun
ities.12 Requiring GMP certification for medical cannabis products
could, however, result in a 2-tier regulatory system (with GPP and
GMP certification required for recreational and medical cannabis
products, respectively), and some producers may elect to exit the
medical cannabis market. We suggest that, to ensure adequate
supply of GMP-certified products and to provide sufficient sup
port for pediatric clinical trials, government incentives could be
offered (e.g., patents and market exclusivity, like those provided
to traditional pharmaceutical companies).
Community pharmacies could be allowed to dispense and
compound medical cannabis products, as most already have the
necessary infrastructure and supply chains in place for ordering
and storing controlled substances. As pharmacists are trained to
assess drug–drug interactions and adverse effects, we support
the Canadian Pharmacist Association position statement on
medical cannabis, which states that pharmacists are best suited
to advise patients and oversee the safe storage and dispensing of
medical cannabis.13
Health Canada should stratify data on medical cannabis use
by age and formulation and mandate the reporting of all ser
ious adverse effects associated with medical cannabis, includ
ing by pharmacists. Reporting could be through the Canada
Vigilance Program, in conjunction with the existing Canadian
Paediatric Surveillance Program. Any reporting system should
be widely accessible (i.e., by computer or phone app) and be
quick and easy to use.
Lastly, a mechanism for adequate research funding, independ
ent of industry, is required. Successfully established national
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health care providers from prescribing cannabis and prevents
cannabis extracts from being placed on provincial and territorial
drug formularies or covered by many private health insurance
plans.8 Consequently, medical cannabis extracts are prohibitively
expensive for many caregivers of children, which often leads
them to turn to the recreational market or produce homemade
extracts that may be unsafe.8
Research on medical cannabis use among children in Canada
is hampered by inadequate national data. Health Canada reports
statistics on medical cannabis use, yet these are currently not
stratified by age. Health Canada also maintains a system for
reporting adverse events associated with cannabis products on
its Canada Vigilance website.9 Licensed cannabis producers are
required to report serious adverse events associated with the use
of their products, but it is not mandatory for health care provid
ers to do so. As patients are likely to report adverse events to
their health care providers or seek medical attention when a ser
ious adverse event occurs, these may not be reported to Health
Canada. Having national data on indications for use and adverse
events, as well as the types of medical cannabis products and
doses used in children would be invaluable.
Effectiveness research is also hampered by current regulation
of cannabis production, which has resulted in the use of medical
cannabis products for children rapidly outpacing the knowledge
base informed from clinical trials. The production, labelling and
distribution of medical and recreational cannabis follow the
Health Canada’s Good Production Practices (GPP), conferring
confidence in their quality.5 In contrast, Health Canada’s Good
Manufacturing Practices (GMP) for pharmaceutical and natural
health products would require more stringent documentation
and additional testing to quantify THC and CBD concentrations.
Recent changes made by Health Canada require cannabis prod
ucts used in clinical trials to have both GMP certification and an
investigator’s brochure.10 Most licensed cannabis producers have
neither the resources nor the expertise to perform the preclinical
research required to produce an investigator’s brochure on their
products, which substantially limits the availability of products
that can be used in clinical trials. Furthermore, the high cost of
conducting clinical trials, combined with a lack of funding oppor
tunities independent of industry, hamper good research. To
address the gap in funding, research partnerships are being
formed between some of the licensed cannabis producers and
Canadian academic institutions, but this raises concerns about
the independence of the resultant research.
In addition to the lack of high-quality research — specifically,
evidence regarding the potential long-term neurodevelopmental
effects of cannabis exposure in children — insufficient education
for health professionals on the indications, efficacy, dosage and
safety of medical cannabis products contributes to their reluc
tance to authorize its use in children.11 Furthermore, regulatory
discrepancies between each province’s and territory’s physician
regulators adds to health care provider uncertainty about the
appropriateness of authorizing medical cannabis to children.
Current processes and regulations could be improved in sev
eral ways to better support the safe use of cannabinoids in
children.
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research infrastructure is already in place with organizations such
as the Canadian Childhood Cannabinoid Clinical Trials (C4T) Con
sortium (www.C4Trials.org), the Canadian Consortium for the
Investigations of Cannabinoids and the Cannabinoid Research
Initiative of Saskatchewan. These bodies are equipped to conduct
high-quality, multicentre pediatric medical cannabis research in
Canada. If adequate funding were made available, Canada would
be well positioned to contribute greatly to the evidence base sup
porting the safe and effective use of medical cannabis for children
whose treatment needs are otherwise inadequately met. Private–
public partnerships can play an important part in ensuring research
funding. For instance, a partnership between the Jim Pattison Chil
dren’s Hospital Foundation, the Children’s Hospital Foundation of
Manitoba, along with Saskatchewan Health Research Foundation
and Research Manitoba is being developed to provide a mechanism
for licensed producers to donate nondirected funds dedicated to
pediatric cannabis research. Once established, researchers will be
able to apply for funding using the peer-review processes of the
Saskatchewan Health Research Foundation and Research Mani
toba. Intergovernmental coordination to ensure earmarking of a
percentage of taxation revenues from recreational cannabis sales
for research (including research on pediatric cannabis use) would
also foster a better evidence base.
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